Previous close | 1.2500 |
Open | 1.2500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 110.00 |
Expiry date | 2025-01-17 |
Day's range | 1.2500 - 1.2500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.